Dudediligence.

Oragenics, Inc

OGENAMEX · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$2.5MSep ’24−$3.3MDec ’24−$2.2MMar ’25−$2.3MJun ’25−$3.1MSep ’25−$2.3MDec ’25−$2.2MMar ’26−$2.5MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$86,987$131,521$37,653none on filenone on file
Operating income−$15.8M−$14.4M−$20.9M−$10.6M−$9.4M
Net income−$15.7M−$14.3M−$20.7M−$10.6M−$9.8M
Operating cash flow−$13.5M−$15.2M−$7.3M−$8.6M−$9.2M
Free cash flow−$13.5M−$15.4Mnone on filenone on filenone on file
Cash$27.3M$11.4M$3.5M$864,840$4.4M
Shares outstanding2.0M2.0M3.1M419.0K4.3M